Nima Sharifi: MVP suggests HSD3B1 is most common inherited driver of prostate cancer mortality
Nima Sharifi,
“Congrats Rana McKay and MVP on JAMA Network Open story showing HSD3B1 prostate cancer mortality in 5200 men! MVP suggests HSD3B1 is most common inherited driver of prostate cancer mortality. Our commentary Lina Schiffer explains our long obsession with HSD3B1.
MVP story is huge because it is culmination starting from our studies at the bench and discovery of cellular metabolic phenotypes–supported by PCF Science, National Cancer Institute, ACS Research across institutions supporting our work at UT Southwestern Medical Center, Cleveland Clinic, Desai Sethi Urology Institute, Sylvester Comprehensive Cancer Center.
Read MVP paper here and our commentary. Unlike other intermediate monogenic drivers of mortality (BRCA2, etc.), there’s no association between HSD3B1 and intermediate clinical factors, e.g., path. Effect on outcomes and mortality ONLY after ADT. Time to start use IMO!”
Visit the article website.
Source: Nima Sharifi/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023